OMS721

FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
CP Wire
Omeros
OMS721
stem cells
thrombotic microangiopathy
Flag link:
FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros
OMS721
stem cell
thrombotic microangiopathy
Flag link:
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
CP Wire
Omeros
OMS721
thrombotic microangiopathy
Flag link:
Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation
Omeros
OMS721
thrombotic microangiopathy
Flag link:
Omeros defends its drug, but still won’t answer basic questions
Omeros defends its drug, but still won’t answer basic questions
Stat
Omeros
OMS721
Flag link:
Omeros Kidney Drug Reports Good Results
Omeros Kidney Drug Reports Good Results
Investopedia
Omeros
OMS721
kidney disease
Flag link:
Omeros' Pipeline Is Largely Neglected
Omeros' Pipeline Is Largely Neglected
Seeking Alpha
Omeros
OMS824
OMS721
Qmidria
Flag link:
FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests
FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests
Bizjournals.com
FDA
fast track
Omeros
OMS721
kidney disease
Flag link:
Omeros Corporation: Another Biotech Bubble In The Making?
Omeros Corporation: Another Biotech Bubble In The Making?
Yahoo/Benzinga
Omeros
OMS721
Soliris
aHUS
Flag link:
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
Motley Fool
Medicines Company
Omeros
OPKO Health
Vivus
OMS721
Qsymia
Fibrocaps
Flag link:
Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
Motley Fool
Dendreon
AbbVie
Omeros
Provenge
prostate cancer
ABT-450
hepatitis C
OMS721
Flag link:
Omeros' OMS721 shows positive Phase 1 clinical trial results
Omeros' OMS721 shows positive Phase 1 clinical trial results
Yahoo/Fly on the Wall
Omeros
OMS721
Flag link: